# Mxt Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mxt-biotech-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.mxtbiotech.com
- Total disclosed funding: $4.3M
- Latest round: Series A (May 16, 2022)
- Investors on record: 6

## About

Based in Seoul, South Korea, and founded in 2021 by CEO Aram Chung, MxT Biotech Co., Ltd. a.k.a. MxT Biotech develops microfluidic-based intracellular substance delivery and gene correction services. The company also provides automated process equipment for the mass production of cell therapeutics. In May 2022, Mxt Biotech Co., Ltd. raised KRW 5 billion in a Series A funding from BNK Venture Capital, DAYLI Partners, Hyundai Investment Partners, We Ventures Partners, and AJU IB Investment.

The company’s technology includes Hydroporator, a non-virus-based intracellular material delivery platform used for the delivery of external cargos like proteins, mRNA, plasmid DNA, nanoparticles, and CRISPR-Cas9 RNPs into the primary cells for cancer immunotherapy, cellular engineering, and genome editing.

## Funding rounds

- Series A, May 16, 2022, $3.9M — AJU IB Investment, BNK Venture Capital, Hyundai Investment Partners, DAYLI Partners, We Ventures
- Seed, Apr 30, 2021, $0.5M — AJU IB Investment, Boditech Med

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Seed, Series A
- Boditech Med — Seed
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series A
- Hyundai Investment Partners (https://capitalatlas.ai/funds/hyundai-investment-partners) — Series A
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A
- We Ventures — Series A